HIV AND AIDS PATIENTS IN LIMBO:
AIDS DRUG ASSISTANCE PROGRAMS
AND THE PRESCRIPTION DRUG BENEFIT
| October 14, 2004 | Contacts: |
Alfred
Chiplin, Esq. achiplin@medicareadvocacy.org (202) 293-5760 |
Vicki Gottlich, Esq. vgottlich@medicareadvocacy.org (202) 293-5760 |
NOTE: This is the
first of a three-part Alert series that the Center for Medicare Advocacy, Inc.
is publishing regarding the implications of the Medicare Modernization Act of
2003 for AIDS Drug Assistance Programs (ADAPs). This first Alert reviews ADAP
programs' current functions. The second CMA Alert will examine the relationship
between Part D and ADAPs. The third CMA Alert will explore the various
mechanisms states use to purchase HIV/AIDS drugs.
The Medicare Modernization Act (MMA) of 2003 will shift prescription drug
coverage for many HIV and AIDS patients to Medicare from a variety of other
health financing programs. This shift raises several questions about where the
11,000 HIV/AIDS patients who currently get prescription drug coverage through
AIDS Drug Assistance Programs (ADAPs) will get their drugs, and who will pay for
them. ADAPs are a crucial source of coverage for many low-income HIV/AIDS
patients who typically face over $10,000 in drug costs each year. Although
ADAPs struggle to provide a maximum amount of coverage, the transfer of
11,000 clients to the Medicare program will not necessarily alleviate their
financial burdens.
ADAPs are the third largest source of federal funding for HIV care, after
Medicaid and Medicare, according to the Kaiser Family Foundation. ADAP funds
come mostly from earmarked allocations under Title II of the Ryan White
Comprehensive AIDS Resources Emergency (CARE) Act. In FY 2003 72% of the $961.5
million national ADAP budget was from earmarked funds. States provided the
second largest source of funding (18%), although this varied widely from state
to state, with some states providing no funding at all. The remainder of the
national ADAP budget was provided through CARE Act Title I and Title II Base
funds, ADAP Supplemental funds, and other federal funds. This funding structure
makes ADAPs particularly vulnerable to changes in federal and state budgets.
Contrary to Medicare, ADAPs are not entitlement programs; they must meet their
clients’ needs with the money provided to them, versus having a budget that
reflects the number of clients enrolled in the program. (Kaiser Family
Foundation, HIV/AIDS Policy Fact Sheet, May 2004.
Click here to view the factsheet.)
Because funding is so variable, many states have implemented cost-control
measures that may involve stricter eligibility requirements, more limited drug
formularies, and higher cost-sharing. Each state determines ADAP eligibility
based on income as a percent of the Federal Poverty Level (FPL), with limits
ranging from 125% of FPL to over 500% of FPL. States also limit formularies,
ranging from 18 drugs in Colorado to 474 in New York. Only four states have
open formularies. Eleven states had waiting lists as of June 2004. For an in-depth study of ADAPs, including a complete state-by-state summary of eligibility
requirements, see the National ADAP Monitoring Project’s Annual Report at
www.atdn.org/access/adap/.
ADAPs were incorporated into the Ryan White CARE Act in 1990 and are
administered by states. They are an important source of prescription drug
coverage for HIV/AIDS patients with little or no drug coverage and serve as a
payer of last resort. In its 2002 Ryan White CARE Act Annual Data Summary, the
Health Resources and Services Administration (HRSA) reported that 136,000
HIV/AIDS patients, or 15% of the total HIV/AIDS population, received
prescription drug coverage through ADAPs. Of these, the National ADAP
Monitoring Project estimates that, in 2003, 8% were also covered by Medicare,
while 7% had Medicaid and 13% had private insurance. The report did not specify
whether the Medicare and Medicaid populations were dually-eligible individuals,
but did report that over 80% of ADAP clients had incomes at or below 200% of the
Federal Poverty Level (FPL).
The Centers for Disease Control and Prevention estimates that approximately
887,000 people have been diagnosed with AIDS in the United States as of 2002.
Many of these people qualify for Medicare because they have received Social
Security Disability Insurance benefits for at least 24 months. Even with help
from federal programs, HIV/AIDS patients have had to piece together their
prescription drug coverage through a number of avenues, including private
insurance, Medicaid, and AIDS Drug Assistance Programs (ADAPs).
Copyright © Center for Medicare Advocacy, Inc. 01/08/2010